Showing results (181-190 of 389) with videos related to
Sort By:
Pageof 39
Molecular Cancer Therapeutics|March 19, 2008
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthaseTakafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, et al.Lung Cancer (Amsterdam, Netherlands)|April 5, 2021
Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancerRie Furukawa, Hiroyuki Inoue, Yasuto Yoneshima, et al.Plos One|November 17, 2015
Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal CancerKimio Yonesaka, Naoki Takegawa, Taroh Satoh, et al.Investigational New Drugs|September 18, 2009
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancerIsamu Okamoto, Masaki Miyazaki, Ryotaro Morinaga, et al.Investigational New Drugs|August 27, 2013
A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary siteAsuka Tsuya, Takayasu Kurata, Akihiro Tamiya, et al.Oncotarget|September 30, 2015
The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancerKimio Yonesaka, Keita Kudo, Satomi Nishida, et al.ERJ Open Research|June 1, 2023
Expansion of ST2-expressing macrophages in a patient with bronchiolitis obliterans syndromeToyoshi Yanagihara, Kentaro Hata, Kunihiro Suzuki, et al.Molecular Cancer Therapeutics|August 19, 2010
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutationWataru Okamoto, Isamu Okamoto, Kaoru Tanaka, et al.Current Medical Research and Opinion|March 10, 2017
Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studiesIsamu Okamoto, Wolfgang H W Schuette, Thomas E Stinchcombe, et al.The Journal of Biological Chemistry|December 3, 2003
Deregulation and mislocalization of the cytokinesis regulator ECT2 activate the Rho signaling pathways leading to malignant transformationShin'ichi Saito, Xiu-Fen Liu, Keiju Kamijo, et al.Pageof 39